UBI gets first test-strip order from Siemens
Universal Biosensors (ASX:UBI) has received its first commercial order from Siemens Healthcare Diagnostics for the supply of test strips for a point-of-care coagulation testing product.
The order for the production and supply of PT-INR test strips is a key milestone in the two companies’ collaboration to develop handheld coagulation testing devices.
The Siemens PT-INR testing system is designed to monitor the application of anti-coagulant therapy Warfarin. Pending regulatory approvals, the system is on track to launch by the end of the third quarter.
Universal Biosensors will manufacture the PT-INR strips for the order at its Rowville, Victoria, plant.
The company’s collaboration with Siemens involves the development of three point-of-care testing products designed to provide laboratory-quality results.
“The receipt of this first commercial order is a major step forward in our program with Siemens towards our shared vision for bringing a range of new products to the point-of-care coagulation testing market,” Universal Biosensors CEO Paul Wright commented.
Universal Biosensors (ASX:UBI) shares were trading 23.08% higher at $0.24 as of around 1.30 pm on Tuesday.
Single-cell sequencing capability boosted in South Australia
The South Australian Genomics Centre has become the first certified service provider in...
Biomaterial helps to reverse aging in the heart
The discovery could open the door to therapies that rejuvenate the heart by changing its cellular...
mRNA used to force HIV out of hiding
Using the same technology behind mRNA COVID-19 vaccines, researchers have discovered a way to...
